Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q4 FY25 Earnings Presentation
32 slides from Suraksha Diagnostic's earnings presentation, 2025
Slide 1: Suraksha Diagnostic Limited Q4 & FY25 Investor Presentation
Suraksha Diagnostic Limited Q4 & FY25 Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q4 & FY25 Highlights
Q4 & FY25 Highlights 3
Slide 4: Consolidated Financial Performance – FY25
Consolidated Financial Performance – FY25 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 33.7% 33.8% 10.6% 12.3% +15% +16% +34% 2,559 851 310 2,223 736 231 FY24 FY25 FY24 FY25 FY24 FY25 4
Slide 5: Consolidated Financial Performance – Q4 FY25
Consolidated Financial Performance – Q4 FY25 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 37.1% 31.7% 30.7% 11.5% 10.1% 11.0% +17% -2% +13% 659 204 200 72 601 189 562 63 60 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 5
Slide 6: Consistent Performance Over the Years
Consistent Performance Over the Years ROE % ROCE % Number of Tests (million) 16.29 23.30 6.69 14.09 21.46 5.98 5.17 9.05 4.32 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Number of Centres Revenue / Patient (₹) EBITDA / Patient(₹) +24% 55 67% 2118 48 1922 715 43 1712 647 427 FY23 FY24 FY25 FY23 FY24
Slide 7: Expanding Offerings Through Strategic Acquisition
Expanding Offerings Through Strategic Acquisition Key Highlights of Strategic Investment In March 2025, the Board approved a proposal for a strategic investment in Fetomat Upon deal completion in April 2025, we held 63% stake in Fetomat ABOUT FETOMAT • Incorporated in May 2021, Fetomat Wellness Priv
Slide 8: Profit & Loss Statement (Consolidated)
Profit & Loss Statement (Consolidated) Particulars (₹ million) Q4 FY25 Q4 FY24 Y-o-Y Q3 FY25 Q-o-Q FY25 FY24 Y-o-Y Revenue from Operations 650.95 551.88 595.13 2520.93 2187.09 Other Income 8.17 9.79 5.99 38.46 35.51 Total Revenue 659.12 561.67 17.35% 601.12 9.65% 2559.39 2222.59 15.15% Cost of Mater
Slide 9: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Particulars (₹ million) FY25 FY24 Particulars (₹ million) FY25 FY24 Property, plant and equipment 1,471.37 1,350.50 Equity share capital 104.16 69.00 Capital work-in-progress 100.99 13.13 Instruments entirely equity in nature - 16.29 Other equity 2,008.24 1,708.80 Right-
Slide 10: Cash Flow Statement (Consolidated)
Cash Flow Statement (Consolidated) Particulars (₹ million) FY25 FY24 Particulars (₹ million) FY25 FY24 Cash flow from operating activities Other financial liabilities 9.15 -1.77 Profit before tax 414.05 314.52 Provisions 1.04 0.50 Adjustments for: Cash generated from operations 739.41 690.92 Depreci
Slide 11: KPIs for FY25
KPIs for FY25 Particulars Units FY25 Particulars Units FY25 Particulars Units FY25 Unit in (₹ in Number of tests per patient^ Unit 5.52 Number of tests performed 6.69 Revenue from operations 2,520.93 million million) Revenue generated from East Number of Small centres Unit 26 (₹ in % 100 Restated pr
Slide 12: Company Overview
Clinic & Diagnostics
Slide 13: Business at a Glance
Business at a Glance as of 31 March, 2025 9 1.19 million 6.69 million ₹ 2,118 Labs Patients Served Tests Performed Revenue per patient (FY25) (FY25) (FY25) 55 313 26 ₹ 715 Diagnostic Centres Doctors CT Machines EBITDA per patient (FY25) 171 4 14 ₹ 280 million Collection Centres NABL accredited labs
Slide 14: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India 1992 2010 2016 2024 Built fully comprehensive 5 centres Received second round of 53 centres diagnostic centre, under funding from OrbiMed brand ‘Suraksha’ Exit of Lighthouse Funds 9 Labs 2007 2013 25 centres 2020 IPO and listing on B
Slide 15: Deeply Entrenched in the Vital Geography of West Bengal
Deeply Entrenched in the Vital Geography of West Bengal 2 2 52 Centers in West Bengal No. of centres >10 centres 1 3 centres 2 centres 1 centres Bihar Assam • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya chained diagnostic centers West Beng
Slide 16: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large MRI CT Scan USG Gastroenterology Neurology Pathology Centres 30-40 5,000 – 8,000 sq. ft X-Ray Cardiology Mammo OPG Dexa Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan USG X-Ray Neurol
Slide 17: …..with Demonstrated Success
…..with Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 8 Satellite Labs 14 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 18: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #14 #1 Hub Centre Flagship Reference Lab Doctor #8 #39 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 19: Well Equipped Clinical Infrastructure
Well Equipped Clinical Infrastructure Suraksha Diagnostic Limited| Investor Presentation 19
Slide 20: Customer Convenience through Value Added Services
Customer Convenience through Value Added Services Customer Centric Approach Value Added Services enhancing customer experience and convenience Home Polyclinic Online SMS Alerts Collection Chambers Bookings Allows samples to be Customers receive an Polyclinic chambers Customers can book collected fro
Slide 21: Experienced Board of Directors
Experienced Board of Directors Dr. Somnath Chatterjee Ritu Mittal Chairman & Joint Managing Director Joint Managing Director & Chief Executive Officer o Associated with Suraksha since incorporation; 32+ years of experience in o Associated with Suraksha since incorporation; 28+ years of experience in
Slide 22: Dynamic and Diverse Management Team to Deliver the Next Phase of Growth
Dynamic and Diverse Management Team to Deliver the Next Phase of Growth Ravindra K S Mamta Jain Group Chief Financial Officer Company Secretary & Compliance Officer Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group
Slide 23: Strategy and Outlook
Strategy and Outlook 23
Slide 24: Leveraging Strengths to Drive Competitive Advantage
Leveraging Strengths to Drive Competitive Advantage Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the 01 high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North- Eastern India Integrated diagnostics
Slide 25: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services 132 1,000+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers Model of integrated pathology, radiology and medica
Slide 26: Strategies to Drive Future Growth
Strategies to Drive Future Growth Expand in adjacent Increase share of Engage in Business- Supplement organic Leverage technology Strengthen position geographies of medical consultation to-Business (“B2B”) growth with selective to elevate customer in core geography Eastern and North- services at dia
Slide 27: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography by Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Ide
Slide 28: Industry Overview
Industry Overview 28
Slide 29: Industry: Poised for High Growth; Shifting Towards Organized Market
Industry: Poised for High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 30: Eastern India - An "Underserved" Market with Premium Pricing
Eastern India - An “Underserved” Market with Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 31: Key Awards & Recognition
Key Awards & Recognition 2017 Best quality in 2019 Best customer service 2021 Business leader service delivery(1) in healthcare(1) of the year(2) Certificate of excellence Outstanding 2021 Awards & certificate 2022 2023 in exemplary trust & diagnostic chain of of excellence(3) commitment towards eas
Slide 32: Thank You
For further information, please contact: Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Thank You Investor Relations Advisors : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension